{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:16:59Z","timestamp":1699957019903},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1157\/13110209","type":"journal-article","created":{"date-parts":[[2007,10,8]],"date-time":"2007-10-08T16:45:29Z","timestamp":1191861929000},"page":"361-365","source":"Crossref","is-referenced-by-count":6,"title":["Impacto de la reducci\u00f3n de dosis de estavudina en su perfil de eficacia\/seguridad en pacientes con infecci\u00f3n por el virus de la inmunodeficiencia humana inmunol\u00f3gica y virol\u00f3gicamente estables"],"prefix":"10.1016","volume":"129","author":[{"given":"Enric","family":"Pedrol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teodoro","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Angel del Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Cart\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Jos\u00e9","family":"Jusdado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piedad","family":"Arazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteve","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Deig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13110209_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-years randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1157\/13110209_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350100603S03","article-title":"Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide drug exposure","volume":"6","author":"Miller","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1157\/13110209_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reversetranscriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J Infec Dis"},{"key":"10.1157\/13110209_bib4","unstructured":"U. S. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents \u2013 Oct 10, 2006. Disponible en: http:\/\/www.aidsinfo.nih.gov\/"},{"key":"10.1157\/13110209_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7326\/0003-4819-126-5-199703010-00003","article-title":"Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients","volume":"126","author":"Spruance","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1157\/13110209_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00002030-200002180-00009","article-title":"Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hidroxyurea","volume":"14","author":"Moore","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13110209_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/01.aids.0000131343.53419.04","article-title":"Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results","volume":"18","author":"Domingo","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13110209_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00126334-200305010-00005","article-title":"Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients","volume":"33","author":"John","year":"2003","journal-title":"JAIDS"},{"key":"10.1157\/13110209_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1157\/13077376","article-title":"Tratamiento de la hiperlactatemia sintom\u00e1tica y de la acidosis l\u00e1ctica en pacientes con infecci\u00f3n por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa an\u00e1logos de los nucle\u00f3sidos","volume":"125","author":"Pedrol","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13110209_bib10","unstructured":"Ficha t\u00e9cnica Zerit\u00ae."},{"key":"10.1157\/13110209_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1157\/13110209_bib12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJM199010113231501","article-title":"A randomized controlled trial of a reduced daily dose of zidovudine in patients with AIDS","volume":"323","author":"Fischl","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1157\/13110209_bib13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJM199010113231502","article-title":"A pilot study of lowe-dose zidovudine in HIV infection","volume":"323","author":"Collier","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1157\/13110209_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2169\/internalmedicine.31.871","article-title":"A randomized trial of reduced doses of azidothymidine in japanese patients with HIV type 1 infection","volume":"31","author":"Kimura","year":"1992","journal-title":"Intern Med"},{"issue":"Suppl 2","key":"10.1157\/13110209_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/infdis\/171.Supplement_2.S131","article-title":"Dose-related activity of stavudine in patients infected with human immunodeficiency virus","volume":"171","author":"Petersen","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1157\/13110209_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm0595-417","article-title":"Mitochondrial toxicity of antiviral drugs","volume":"1","author":"Lewis","year":"1995","journal-title":"Nat Med"},{"key":"10.1157\/13110209_bib17","unstructured":"Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Suankratay C, et al. Reduction of d4T dosages improves lipoatrophy without virologic failure [resumen 749]. Actas de 2nd IAS Conference on HIV Pathogenetics and treatment; 2003; Paris."},{"key":"10.1157\/13110209_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1310\/11PP-PG9W-FUJT-64YL","article-title":"Long-term efficacy of a protease inhibitor sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage","volume":"5","author":"Shalit","year":"2004","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13110209_bib19","series-title":"Actas de 9th European AIDS Conference","article-title":"Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-1 infected patients [resumen 9.4\/2]","author":"Delpierre","year":"2003"},{"key":"10.1157\/13110209_bib20","series-title":"Actas de 9th European AIDS Conference","article-title":"Low dose stavudine: as effective as standard dose but less side effects [resumen 9.8\/5]","author":"Koegl","year":"2003"},{"key":"10.1157\/13110209_bib21","unstructured":"Urbina A, Jibilian A, Nibbe Y, Maa JF, Wang S. Long term use of low dose stavudine is effective and well tolerated [resumen TuPe2.2B31]. Actas de 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005, julio 24-27; Rio de Janeiro. Rio de Janeiro: IAS; 2005."},{"key":"10.1157\/13110209_bib22","series-title":"10th European AIDS Conference","article-title":"Evaluation of viral efficacy and safety of a reduced dose of stavudine: the Phoenix study [resumen PE7.3\/19]","author":"Ait-Mohand","year":"2005"},{"key":"10.1157\/13110209_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1310\/ED57-EU48-RK6A-E5U0","article-title":"Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity","volume":"6","author":"S\u00e1nchez-Conde","year":"2005","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13110209_bib24","series-title":"Actas de 3rd IAS Conference on HIV Pathogenesis and Treatment","article-title":"A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-na\u00efve patients (ETOX study) [resumen TuPe2.4C10]","author":"Ribera","year":"2005"},{"key":"10.1157\/13110209_bib25","series-title":"Actas de 12th Conference on Retroviruses and Opportunistic Infections","article-title":"Influence of host and disease factors on ART-associated co-morbidities [resumen 852]","author":"Lichtenstein","year":"2005"},{"key":"10.1157\/13110209_bib26","unstructured":"Milinkovic A, L\u00f3pez S, Vidal S, Mir\u00f3 O, Fern\u00e1ndez X, Arnaiz JA, et al. A randomized open study comparing the effect of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. Antivir Ther. En prensa 2007."},{"key":"10.1157\/13110209_bib27","series-title":"Actas de XV International AIDS Conference","article-title":"Optimal d4T-therapy in HIV-1 positive patients from a neurological point of view \u2013lower dose, less side effects, equal effectivity? [resumen WePeB5924]","author":"Haslinger","year":"2004"},{"key":"10.1157\/13110209_bib28","series-title":"Actas de XV International AIDS Conference","article-title":"Efficacy and safety of half dose compared to full dose d4T and AZT in combination with ddI in Thai HIV-infected patients: 96 weeks results of ACTT002\/ARV065 study [resumen We-PeB5952]","author":"Siangphoe","year":"2004"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775307728555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775307728555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T10:22:39Z","timestamp":1684059759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775307728555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0025775307728555"],"URL":"https:\/\/doi.org\/10.1157\/13110209","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}